This MicroRNA Might Help Detect, Treat Ovarian Cancer

June 26, 2020 6:00 pm

In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

By Ian Demsky

A microRNA that is normally involved in immune cell differentiation helps to initiate

Read more

Single-Cell Analysis of Ovarian Cancer Points to Potential Treatment Avenue

June 22, 2020 10:00 am

Inhibiting the JAK/STAT pathway could represent a potential treatment for high-grade serous ovarian cancer, according to a single-cell analysis.

Researchers led by the Broad Institute’s Aviv Regev used single-cell RNA sequencing (scRNA-seq) to analyze about 11,000 cells from ascites from … Read more

New Test Paves the Way for Tailored Treatment of Deadliest Form of Ovarian Cancer

June 18, 2020 4:00 pm

University of British Columbia (UBC) researchers have led an international team in developing a new test to better diagnose different types of ovarian cancer, a tool that could one day guide and improve treatment options for women diagnosed with the … Read more

‘We Have a Job to Do’: Cancer Patients and Their Doctors Carry on With Clinical Trials During Covid-19

June 17, 2020 5:00 pm

By Elizabeth Cooney

Cancer isn’t waiting for Covid-19 to go away. Neither is Karen Howley.

Diagnosed two years ago with advanced ovarian cancer, Howley started on a new experimental drug in mid-March, just as coronavirus case counts were soaring in … Read more

Berzosertib: Protein-Targeting Drug Used to Treat Cancer May Have Same Effect on Coronavirus

June 16, 2020 7:00 pm

Scientists have begun using berzosertib, a protein-targeting drug, as an accompaniment to chemotherapy for patients with ovarian cancer. The drug is currently in its second phase of trials with cancer patients and is showing promising results for how it … Read more

FDA Approves Pembrolizumab for TMB-High Tumors

June 16, 2020 3:00 am

The FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden–high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options.Read more

Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

June 5, 2020 8:00 am

By Audrey Sternberg

The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer.

The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib … Read more

Final Results of KEYNOTE-100 for Patients With Advanced Ovarian Cancer

June 3, 2020 5:00 pm

Pembrolizumab monotherapy continues to show modest antitumor activity in patients with recurrent advanced ovarian cancer, according to updated results of the KEYNOTE-100 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020).

In the interim … Read more

Convenient Spit Test Helps Women Assess Cancer Risk From The Comfort Of Their Own Homes

June 1, 2020 4:00 pm

By Stand Up To Cancer

Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don’t get tested. A collaborative Stand Up … Read more

Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer

May 30, 2020 5:00 pm

By Susan Moench, PhD, PA-C

This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.

Early results from a single-arm phase 1b study conducted in … Read more

First Study To Report OS Benefit After Secondary Cytoreductive Surgery in Select Patients With Recurrent Ovarian Cancer

May 29, 2020 5:00 pm

By Susan Moench, PhD, PA-C

According to results of a prospective, randomized clinical trial of selected patients with platinum-sensitive, recurrent ovarian cancer assigned to receive second-line platinum-based chemotherapy preceded by secondary cytoreductive surgery versus not, OS was significantly longer for … Read more

Combined Cediranib and Olaparib Presents Similar Activity to Standard of Care Treatment

May 29, 2020 10:00 am

Combined cediranib and olaparib presents similar activity to standard of care treatment for platinum-sensitive ovarian cancer.

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based … Read more

Recognizing the Complexities of Caregiving

May 27, 2020 4:00 pm

This article touches on the complexities that come with being a caregiver to someone battling cancer, as well as the importance of support, not only for the person they are caring for, but for themselves. Our Steps Through OC programRead more

New Approach to Stress Out Cancer Cells is Effective in Ovarian Cancer

May 26, 2020 10:00 am

Around 1,500 Australian women will be diagnosed with ovarian cancer this year, and one woman will die every eight hours from this disease.

High-grade serous ovarian cancer (HGSOC) is the most common form of ovarian cancer and accounts for 70%-80% … Read more

Gemcitabine–Pazopanib Combo Shows Antitumor Efficacy in Ovarian Cancer

April 17, 2020 11:00 am

Toronto, Canada—Findings from a phase 2 study prepared for presentation at the 2020 SGO Annual Meeting on Women’s Cancer showed that adding pazopanib to gemcitabine enhanced antitumor activity in patients with ovarian cancer.

“Angiogenesis inhibition is a valuable strategy for … Read more

New Cancer Drug Shrinks Tumors, Reduces Side Effects, in Animal Studies

April 15, 2020 10:00 am

By Brita Belli

A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates … Read more

Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status

April 8, 2020 10:00 am

By Gina Columbus

The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more

Certain STIs May Play a Role in Ovarian Cancer Development

April 7, 2020 10:00 am

By Leah Lawrence

History of sexually transmitted infections (STIs) may be important in the etiology of ovarian cancer — and a new study links certain STIs with increased risk for the disease.

Using data from the European Prospective Investigation into … Read more

Trametinib Boosts PFS and Response Rates in Low-Grade Ovarian Cancer

April 7, 2020 10:00 am

By Denise Myshko

Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more